ARTICLE | Clinical News
Sparsentan: Completed Phase II enrollment
April 11, 2016 7:00 AM UTC
Retrophin completed enrollment of >100 patients in the double-blind, international Phase II DUET trial comparing 200, 400 and 800 mg oral RE-021 once daily for 8 weeks vs. once-daily oral irbesartan. ...